Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | KDM1A | O60341 | 3/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL764726 | 0.81 | PTGS1 (0.56) | PTGS1PTGS2HTTKDM1AMAOA | |
| SCHEMBL19658755 | 0.77 | HTT (0.62) | PTGS1PTGS2HTTALDH1A1HPGD | |
| SCHEMBL71414 | 0.76 | PTGS1 (0.62) | PTGS1PTGS2HTTKDM1AMAOA | |
| SCHEMBL17753763 | 0.75 | PTGS1 (0.54) | PTGS1PTGS2HTTKDM1AMAOA | |
| SCHEMBL19658728 | 0.74 | HTT (0.67) | PTGS1PTGS2HTTALDH1A1HPGD | |
| SCHEMBL12086989 | 0.74 | AOC3 (0.55) | PTGS1PTGS2HTTKDM1AMAOA | |
| SCHEMBL25066870 | 0.73 | PTGS1 (0.59) | PTGS1PTGS2HTTKDM1AMAOA | |
| SCHEMBL17541625 | 0.73 | PTGS1 (0.59) | PTGS1PTGS2HTTKDM1AMAOA | |
| SCHEMBL20559648 | 0.73 | PTGS1 (0.59) | PTGS1PTGS2HTTKDM1AMAOA | |
| SCHEMBL1744600 | 0.73 | PTGS1 (0.59) | PTGS1PTGS2HTTKDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260454-B2 | Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals | SANOFI (FR) | 2016-02-16 | — | — | US | disclosed |
| US-20140296169-A1 | ISOTHIAZOLOPYRIDINE-2-CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296169-A1 | ISOTHIAZOLOPYRIDINE-2-CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | TGM2, TGM1, TGM6 | PTGS1 72/4885PTGS2 32/4885HTT 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.